Neurosom closes oversubscribed bridge round — FDA clears NEAT AI software, NIH NIA awards Phase II funding for MCI trial
Summary
Neurosom announced the closing of an oversubscribed bridge round on January 6, 2026, led by Portland Seed Fund's Intrepid Oregon Fund, with the Loomis Family Trust, OEN Angel Syndicate, and ONAMI. Key 2025 milestones that drove investor confidence: FDA clearance of NEAT — their AI-powered software for the Sleep WISP neuromodulation therapy system; National Institute of Aging Phase II funding award for a clinical trial on Mild Cognitive Impairment (MCI); and the 2025 Oregon Entrepreneurs Network Angel Oregon Life & BioScience Fund Investment Award. Sleep WISP uses closed-loop EEG monitoring and brain stimulation during sleep to improve deep and REM sleep, targeting dementia risk reduction. CSO Don Tucker PhD described it as potentially "the first example of AI connected to monitoring the brain's electrical activity and then manipulating that activity in real time."
Why it matters
FDA clearance of NEAT AI software and NIH NIA Phase II funding in the same year — for a pre-seed company — is an extraordinary regulatory and funding achievement. These are independent expert validations of both the technology (FDA) and the scientific merit (NIH NIA). Together they transform the bridge round oversubscription from a faith investment to a data-driven one: investors saw two independent expert bodies endorse the company before writing their checks.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial